Flerie
Flerie is a Stockholm-based, publicly listed evergreen life-science investment company that takes long-term direct minority and majority stakes in biotech, pharma-services and drug-development businesses across the Nordics, wider Europe, Israel and the US. Founded in 2011 by Recipharm co-founder Thomas Eldered, it listed on Nasdaq Stockholm in June 2024 through a reverse merger with InDex Pharmaceuticals and trades as Flerie AB (publ) under the ticker FLERIE.
Key facts
Recent exits
Coverage notes
1 fund tracked, 29 portfolio companies (25 active · 4 realized). Verified weekly from public filings and deal announcements.
Sector breakdown
29 companiesFunds & portfolio
Every fund Flerie has raised, with its portfolio companies. Hand-checked from public filings.
Flerie InvestLife Sciences VCActive2011 · 15yr25 active · 4 realized
Unrealized
25 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech |  Sweden | 2022 | |
| Biotech |  Netherlands | 2018 | |
| Biotech | Sweden | 2022 | |
| Biotech | Sweden | 2017 | |
| Pharma | Sweden | 2022 | |
| Biotech | Sweden | 2021 | |
| Biotech | Sweden | 2021 | |
| ClimateTech | Sweden | 2014 | |
| Biotech | Sweden | 2017 | |
| Biotech | Sweden | 2013 | |
| Biotech | Iceland | 2021 | |
| Pharma |  Germany | 2023 | |
| Biotech |  US | 2022 | |
| Biotech | Israel | 2012 | |
| Biotech | Sweden | 2021 | |
| Biotech | Sweden | 2023 | |
| Biotech |  UK | 2022 | |
| Biotech | Sweden | 2014 | |
| Pharma | Sweden | 2021 | |
| Biotech | UK | 2014 | |
| Biotech | Sweden | 2022 | |
| MedTech | Sweden | 2013 | |
| MedTech | US | 2022 | |
| Biotech | Sweden | 2022 | |
| Pharma | Sweden | 2021 |
Sweden· Entry 2022Netherlands· Entry 2018Sweden· Entry 2022Sweden· Entry 2017Sweden· Entry 2022Sweden· Entry 2021Sweden· Entry 2021Sweden· Entry 2014Sweden· Entry 2017Sweden· Entry 2013Germany· Entry 2023US· Entry 2022Sweden· Entry 2021Sweden· Entry 2023UK· Entry 2022Sweden· Entry 2014Sweden· Entry 2021UK· Entry 2014Sweden· Entry 2022Sweden· Entry 2013US· Entry 2022Sweden· Entry 2022Sweden· Entry 2021Realized
4 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech | Sweden | 2022 | 2025 | Secondary | – | – | |
| Pharma | UK | 2011 | 2020 | Trade Sale | – | ||
| Biotech | Sweden | 2012 | 2016 | Trade Sale | – | ||
| Pharma | US | 2013 | 2025 | – | – | – |
US· Entry 2013Saved GPs appear in your watchlist, one click from your workspace.
Similar firms
Other private equity firms tracked on GP Intel.
Sweden·€351MSweden·€397M
Sweden·€188M
Sweden·€125MSweden·€115M
Sweden·€500MSweden·€92M
Sweden·€80M
Sweden·€21MSweden·€12M
Sweden·€10MSwedenGet the full picture on Flerie.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in